AU771603B2 - Anti-GPR-9-6 and anti-teck antibodies and methods of identifying modulators of GPR-9-6 and teck functions - Google Patents

Anti-GPR-9-6 and anti-teck antibodies and methods of identifying modulators of GPR-9-6 and teck functions Download PDF

Info

Publication number
AU771603B2
AU771603B2 AU35226/00A AU3522600A AU771603B2 AU 771603 B2 AU771603 B2 AU 771603B2 AU 35226/00 A AU35226/00 A AU 35226/00A AU 3522600 A AU3522600 A AU 3522600A AU 771603 B2 AU771603 B2 AU 771603B2
Authority
AU
Australia
Prior art keywords
gpr
antibody
binding
antigen
teck
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
AU35226/00A
Other languages
English (en)
Other versions
AU3522600A (en
Inventor
David P. Andrew
Paul D. Ponath
Brian A. Zabel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Millennium Pharmaceuticals Inc
Original Assignee
Millennium Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23014693&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU771603(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Millennium Pharmaceuticals Inc filed Critical Millennium Pharmaceuticals Inc
Publication of AU3522600A publication Critical patent/AU3522600A/en
Priority to AU2004200592A priority Critical patent/AU2004200592B2/en
Application granted granted Critical
Publication of AU771603B2 publication Critical patent/AU771603B2/en
Anticipated expiration legal-status Critical
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/81—Packaged device or kit
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/975—Kit

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Biomedical Technology (AREA)
  • Transplantation (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
AU35226/00A 1999-03-11 2000-03-10 Anti-GPR-9-6 and anti-teck antibodies and methods of identifying modulators of GPR-9-6 and teck functions Expired AU771603B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2004200592A AU2004200592B2 (en) 1999-03-11 2004-02-13 Anti-GPR-9-6 and anti-teck antibodies and methods of identfying modulators of GPR-9-6 and teck functions

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/266464 1999-03-11
US09/266,464 US6329159B1 (en) 1999-03-11 1999-03-11 Anti-GPR-9-6 antibodies and methods of identifying agents which modulate GPR-9-6 function
PCT/US2000/006240 WO2000053635A1 (en) 1999-03-11 2000-03-10 Anti-gpr-9-6 and anti-teck antibodies and methods of identifying modulators of gpr-9-6 and teck functions

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2004200592A Division AU2004200592B2 (en) 1999-03-11 2004-02-13 Anti-GPR-9-6 and anti-teck antibodies and methods of identfying modulators of GPR-9-6 and teck functions

Publications (2)

Publication Number Publication Date
AU3522600A AU3522600A (en) 2000-09-28
AU771603B2 true AU771603B2 (en) 2004-04-01

Family

ID=23014693

Family Applications (1)

Application Number Title Priority Date Filing Date
AU35226/00A Expired AU771603B2 (en) 1999-03-11 2000-03-10 Anti-GPR-9-6 and anti-teck antibodies and methods of identifying modulators of GPR-9-6 and teck functions

Country Status (7)

Country Link
US (6) US6329159B1 (enExample)
EP (1) EP1157043B2 (enExample)
JP (2) JP5112578B2 (enExample)
AT (1) ATE517123T1 (enExample)
AU (1) AU771603B2 (enExample)
CA (1) CA2365230C (enExample)
WO (1) WO2000053635A1 (enExample)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1083889T3 (da) * 1998-06-01 2004-04-13 Ortho Mcneil Pharm Inc Tetrahydronaphthalenforbindelser og deres anvendelse til behandling af neurodegenerative sygdomme
US20050100548A1 (en) * 2001-07-24 2005-05-12 Biogen Idec Ma Inc. BAFF, inhibitors thereof and their use in the modulation of B-cell response
US6329159B1 (en) 1999-03-11 2001-12-11 Millennium Pharmaceuticals, Inc. Anti-GPR-9-6 antibodies and methods of identifying agents which modulate GPR-9-6 function
US6698636B2 (en) * 2000-09-28 2004-03-02 June Angus Waist pouch
US7468253B2 (en) * 2001-06-07 2008-12-23 Chemocentryx, Inc. Method for multiple chemokine receptor screening for antagonists using RAM assay
JP4233092B2 (ja) * 2001-06-07 2009-03-04 ケモセントリックス， インコーポレイテッド 細胞移動アッセイ
NO20013192L (no) * 2001-06-25 2002-12-27 Medinnova As Metode for monitering av T-celler
US7871619B2 (en) * 2001-11-30 2011-01-18 Chemocentryx, Inc. Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors
US7413866B2 (en) * 2001-11-30 2008-08-19 Chemocentryx, Inc. Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors
US7253007B2 (en) * 2001-11-30 2007-08-07 Chemocentryx, Inc. Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors
US7442512B2 (en) * 2001-11-30 2008-10-28 Chemocentryx, Inc. Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors
AU2003229767A1 (en) * 2002-05-14 2003-11-11 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with chemokine receptor 9(ccr9)
NZ566263A (en) * 2002-05-24 2009-09-25 Millennium Pharm Inc CCR9 inhibitors and methods of use thereof
US8658377B2 (en) 2002-11-15 2014-02-25 Morehouse School Of Medicine Detecting cancer with anti-CCL25 and anti-CCR9 antibodies
WO2004045526A2 (en) * 2002-11-15 2004-06-03 Morehouse School Of Medicine Anti-chemokine and associated receptors antibodies for inhibition of growth of neoplasms
AU2003294290A1 (en) * 2002-11-15 2004-06-15 Morehouse School Of Medicine Anti-chemokine and associated receptor antibodies and uses for inhibition of inflammation.
US9233120B2 (en) * 2002-11-15 2016-01-12 Jyant Technologies Anti-CCL25 and anti-CCR9 antibodies for the prevention and treatment of cancer and cancer cell migration
US20120135415A1 (en) * 2002-11-15 2012-05-31 Morehouse School Of Medicine Detecting cancer with anti-cxcl13 and anti-cxcr5 antibodies
US8512701B2 (en) * 2002-11-15 2013-08-20 Morehouse School Of Medicine Anti-CXCL13 and anti-CXCR5 antibodies for the prevention and treatment of cancer and cancer cell migration
MXPA05006507A (es) * 2002-12-20 2006-02-17 Chemocentryx Inhibidores de ccxckr2 expresado en tumor humano.
BRPI0410495A (pt) 2003-04-23 2006-06-13 Medarex Inc composição para o tratamento de uma doença inflamatória dos intestinos e uso de um antagonista de interferon tipo i para preparar um medicamento
US20100247540A1 (en) * 2003-10-30 2010-09-30 Chemocentryx, Inc. Methods and Compositions For Modulating Angiogenesis
CN1997893A (zh) * 2004-04-16 2007-07-11 健泰科生物技术公司 抗体测定法
ES2526194T3 (es) 2004-06-21 2015-01-08 E. R. Squibb & Sons, L.L.C. Anticuerpos del receptor 1 de interferón alfa, y sus usos
WO2006116319A2 (en) * 2005-04-21 2006-11-02 Chemocentryx, Inc. Reagents that bind ccx-ckr2
CA2883711A1 (en) 2012-09-07 2014-03-13 The Governors Of The University Of Alberta Methods and compositions for diagnosis of inflammatory liver disease
EP2876114A1 (en) * 2013-11-25 2015-05-27 Consejo Superior De Investigaciones Científicas Antibodies against CCR9 and applications thereof
US20200164068A1 (en) 2016-02-16 2020-05-28 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Modulators of tumor immune resistance for the treatment of cancer
WO2017140793A1 (en) 2016-02-16 2017-08-24 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Modulators of ccr9 for treating tumor resistance to immune responses
EP3551047A1 (en) 2016-12-07 2019-10-16 Progenity, Inc. Gastrointestinal tract detection methods, devices and systems
US10980739B2 (en) 2016-12-14 2021-04-20 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a chemokine/chemokine receptor inhibitor
US20230023414A1 (en) 2018-11-19 2023-01-26 Progenity, Inc. Methods and devices for treating a disease with biotherapeutics
US11707610B2 (en) 2019-12-13 2023-07-25 Biora Therapeutics, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
EP4472741A1 (en) 2022-02-03 2024-12-11 SunRock Biopharma S.L. Combination therapy comprising anti-ccr9 antibody and vincristine for cancer
JP7368678B1 (ja) * 2023-04-26 2023-10-25 イミュニティリサーチ株式会社 Ｃｄ４＋ｔ細胞集団中の特定の細胞亜集団の相対量の測定方法
EP4578874A1 (en) * 2023-12-29 2025-07-02 SunRock Biopharma S.L. Anti-ccr9 antibody

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US18167A (en) * 1857-09-08 Improvement in blast-furnaces
US5440021A (en) * 1991-03-29 1995-08-08 Chuntharapai; Anan Antibodies to human IL-8 type B receptor
US5652133A (en) 1993-01-28 1997-07-29 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Cloning and expression of the human macrophage inflammatory protein-1.alpha.α) /rantes receptor
EP2034023A1 (en) * 1996-03-01 2009-03-11 Euroscreen S.A. C-C CKR-5 ,CC-Chemikines receptor, derivatives thereof and their uses
US5981231A (en) 1996-06-17 1999-11-09 Human Genome Sciences, Inc. Polynucleotides encoding chemokine β-15
WO1997048807A1 (en) 1996-06-17 1997-12-24 Human Genome Sciences, Inc. CHEMOKINE β-15
JP2000514295A (ja) 1996-07-05 2000-10-31 シェーリング コーポレイション 哺乳動物のケモカイン試薬
US6723520B2 (en) * 1996-07-05 2004-04-20 Schering Corporation Antibodies that bind chemokine teck
DE69737656T2 (de) * 1996-09-10 2008-01-03 Theodor Kocher Institut Cxcr3 chemokine rezeptor, antikoerper, nukleinsaeure und deren verfahren zur anwendung
WO1998032858A2 (en) 1997-01-23 1998-07-30 Schering Corporation Mammalian chemokines; receptors; reagents; uses
EP0878542A3 (en) * 1997-04-22 2000-04-19 Smithkline Beecham Corporation cDNA clone HMTMF81 that encodes a novel human 7-transmembrane receptor
WO1999007738A2 (en) * 1997-08-06 1999-02-18 Regeneron Pharmaceuticals, Inc. Human orphan receptor ntr-1
US6329159B1 (en) 1999-03-11 2001-12-11 Millennium Pharmaceuticals, Inc. Anti-GPR-9-6 antibodies and methods of identifying agents which modulate GPR-9-6 function
YU78601A (sh) * 1999-05-05 2005-07-19 Aventis Pharma Deutschland Gmbh. 1-(p-tienilbenzil)-imidazoli kao agonisti angiotenzin-(1-7)- receptora, postupak za njihovu proizvodnju, njihova primena i farmaceutski preparati koji ih sadrže
WO2001049325A2 (en) * 2000-01-07 2001-07-12 Stichting Klinische Farmacologie Groningen Gene therapy to promote angiogenesis and/or the treatment of heart failure
PT1562940E (pt) 2002-11-18 2007-07-23 Chemocentryx Inc Sulfonamidas de arilo.

Also Published As

Publication number Publication date
EP1157043B1 (en) 2011-07-20
US6884574B2 (en) 2005-04-26
US20050181501A1 (en) 2005-08-18
ATE517123T1 (de) 2011-08-15
CA2365230C (en) 2015-11-24
US6329159B1 (en) 2001-12-11
CA2365230A1 (en) 2000-09-14
US20030022238A1 (en) 2003-01-30
JP2002542157A (ja) 2002-12-10
US6689570B2 (en) 2004-02-10
US7485301B2 (en) 2009-02-03
US6936248B1 (en) 2005-08-30
US20020119504A1 (en) 2002-08-29
US20020141991A1 (en) 2002-10-03
JP5933204B2 (ja) 2016-06-08
EP1157043A1 (en) 2001-11-28
WO2000053635A1 (en) 2000-09-14
JP5112578B2 (ja) 2013-01-09
AU3522600A (en) 2000-09-28
JP2012012402A (ja) 2012-01-19
EP1157043B2 (en) 2015-07-22
US7381412B2 (en) 2008-06-03

Similar Documents

Publication Publication Date Title
AU771603B2 (en) Anti-GPR-9-6 and anti-teck antibodies and methods of identifying modulators of GPR-9-6 and teck functions
US6319675B1 (en) Methods for detecting and/or identifying agents which bind and/or modulate function of “bonzo” chemokine receptor
US6528625B1 (en) Anti-CCR5 antibodies and kits comprising same
AU773293B2 (en) Anti-CCR4 antibodies and methods of use therefor
US9163084B2 (en) Antibodies which bind human CXCR3
US7208152B2 (en) Antibodies for “Bonzo” chemokine receptor and therapeutic uses thereof
AU2004200592B2 (en) Anti-GPR-9-6 and anti-teck antibodies and methods of identfying modulators of GPR-9-6 and teck functions
MXPA01007200A (en) Anti-gpr-9-6 and anti-teck antibodies and methods of identifying modulators of gpr-9-6 and teck functions
MXPA01007199A (en) Anti-ccr4 antibodies and methods of use therefor
MXPA01000742A (en) Anti-crr2 antibodies and methods of use therefor

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired